Alkermes Moves to Loss but Beats – Analyst Blog
Zacks Market Commentaries (November 9th, 2009) Writes:
Investing Lessons, Johnson & Johnson, Risperdal Consta;, schizophrenia, Stocks to Watch, USD, Vivitrol, Zacks Market Commentaries
Zacks Market Commentaries (November 9th, 2009) Writes:
Zacks Market Commentaries (October 28th, 2009) Writes:
Zacks Market Commentaries (October 15th, 2009) Writes:
Zacks Market Commentaries (October 14th, 2009) Writes:
Zacks Market Commentaries (October 14th, 2009) Writes:
Dr. Stock Pick (October 12th, 2009) Writes:
Dr Stock Pick HOT News & Alerts!
_________________________________________
FREE Daily Stock Alerts From DrStockPick.com
_________________________________________
DrStockPick.com Watch List!
My Picks for Tuesday October 13, 2009, are:
**************************************************************
VASC, Vascular Solutions Inc.
VASC is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company’s product line consists of five major categories: hemostat (blood clotting) products, extraction (clot removal) catheters, vein products, specialty catheters and access products.
VASC has received Food and Drug Administration clearance to sell the new Guardian II hemostasis valve, which is used in surgery
VASC is the exclusive U.S. distributor for the product, which is made by Ireland-based Zerusa Ltd.
**************************************************************
VNDA, Vanda Pharmaceuticals, Inc.
VNDA is a biopharmaceutical company
...
Zacks Market Commentaries (September 29th, 2009) Writes:
Zacks Market Commentaries (September 3rd, 2009) Writes:
Today morning, Japanese pharmaceutical company Dainippon Sumitomo Pharma Co., Ltd. confirmed that it signed a definitive agreement to buy U.S. pharmaceutical company Sepracor Inc. (SEPR). The deal has been valued at $23 per share or $2.6 billion.
The market was abuzz with rumors yesterday regarding the potential takeover. The rumors led to a 26.46% increase in Sepracor’s stock price. Trading was halted in the afternoon with Sepracor shares closing at $22.80.
This acquisition is the latest in a series of deals conducted by Japanese companies that are looking to tap the U.S. pharmaceutical market – the biggest in the world. Last year, we saw four such deals take place including Eisai’s acquisition of MGI Pharma, Takeda’s acquisition of Millennium Pharma and Shionogi’s acquisition of Sciele. Finally, Daiichi-Sankyo acquired a stake in India’s Ranbaxy Labs.
Following the completion of the acquisition, Sepracor will become a wholly owned subsidiary of Dainippon Sumitomo Pharma America
...
Zacks Market Commentaries (August 28th, 2009) Writes:
For Immediate Release
Chicago, IL – August 28, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alkermes, Inc. (ALKS), Johnson & Johnson (JNJ), AstraZeneca (AZN), Eli Lilly (LLY) and Pfizer (PFE).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Thursday’s Analyst Blog:
Setback for Alkermes’ Pipeline
On Wednesday, Alkermes, Inc. (ALKS) disclosed that it has received notification from Johnson & Johnson’s (JNJ) Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutical International stating that Janssen does not intend to continue with the development of the four-week long-acting injectable formulation of risperidone.
...
Zacks Market Commentaries (August 27th, 2009) Writes: